Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (49)

I-001Noha Abdelgawad

Pharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, and Linezolid in Central Nervous System: Insights from a Rabbit Model of Tuberculosis Meningitis

Wednesday 10:20-11:50

I-011Arkadiusz Adamiszak

Do critically ill patients undergoing continuous renal replacement therapy require ceftaroline dosage adjustments? Ceftaroline PopPK model and dosage simulations with probability of target attainment analysis based on retrospective data.

Wednesday 10:20-11:50

I-013Romain Aubry

Translational PKPD modelling of ceftazidime/avibactam for treatment of carbapenemase-producing Klebsiella pneumoniae in the persistently neutropenic rabbit pneumonia model

Wednesday 10:20-11:50

I-015Salma Bahnasawy

Applying PKPD modelling to evaluate the impact of plasma proteins in time-kill experiments; does the protein binding matter?

Wednesday 10:20-11:50

I-043Nils Bundgaard

Model informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza

Wednesday 10:20-11:50

I-044Nils Bundgaard

Framework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models

Wednesday 10:20-11:50

I-048Jose Miguel Calderin Miranda

Population pharmacokinetic analysis of isoniazid in plasma and cerebrospinal fluid from adults with HIV-associated tuberculosis meningitis

Wednesday 10:20-11:50

I-068Emmanuelle Comets

Modelling the dynamics of bacterial colonisation in a murine model of Urinary Tract Infections

Wednesday 10:20-11:50

I-096Yin Edwards

Pharmacokinetics/pharmacodynamics and exposure-response modelling of VH3810109 (N6LS) in antiretroviral therapy-naïve adults with HIV-1 from the Phase IIa BANNER Study

Wednesday 10:20-11:50

I-103Aneeq Farooq

A pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro.

Wednesday 10:20-11:50

I-116María García-Cremades

Predictors of treatment outcomes in children with rifampicin-resistant tuberculosis: a global individual patient data meta-analysis

Wednesday 10:20-11:50

II-015Silvia Grandoni

Do differences in PK defeat similarities in immune system in non-human primates? Pharmacokinetic modelling of standard of care antitubercular drugs in marmosets

Wednesday 15:20-16:50

II-016

Evaluating empirical dose-response relationships and dosing strategies of bacteriophage therapy using a mechanism-based modeling approach

Wednesday 15:20-16:50

II-026Felix Hammann

Informing BOHEMIA cluster randomized controlled trial ivermectin dose selection in healthy participants in Kenya

Wednesday 15:20-16:50

II-028Miriam Happ

Quantifying the impact of infection on murine antibiotic exposure in the framework of non-conventional treatment modalities within the FAIR study

Wednesday 15:20-16:50

II-035Rasmus Henninger

Preclinical population pharmacokinetic modelling of skin target site exposure of DNDI-0690 and DNDI-6148 in the treatment of cutaneous leishmaniasis

Wednesday 15:20-16:50

II-050Marjorie Imperial

Step-Wise Population Pharmacokinetic Modeling Approach to Characterize Complex Absorption of Lenacapavir Following SC Administration in Healthy Participants

Wednesday 15:20-16:50

II-054Van der Feltz Isabella

Delpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis

Wednesday 15:20-16:50

II-065Woojin Jung

Predicting lung exposure of intramuscular niclosamide as an antiviral agent against COVID-19 using power-law-based pharmacokinetic modeling

Wednesday 15:20-16:50

II-072Allan Kengo

Population pharmacokinetic analysis of the drug interaction between ritonavir-boosted atazanavir and rifampicin

Wednesday 15:20-16:50

II-078Simon Koele

Population pharmacokinetics and exposure-response of BTZ-043 for the treatment of tuberculosis.

Wednesday 15:20-16:50

II-090Anna Largajolli

Clinical Model-Based Meta-Analysis applied to Vaccine Development for SARS-CoV-2 Variants

Wednesday 15:20-16:50

II-095Donghwan Lee

Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients with Population Pharmacoki-netics and Monte-Carlo Simulation

Wednesday 15:20-16:50

II-103Yu-Jou Lin

Model-informed once-daily dosing strategy for children, adolescents and adults for bedaquiline and delamanid

Wednesday 15:20-16:50

II-109Xuanlin Liu

Viral dynamic modeling of nirmatrelvir against SARS-CoV-2 in an in vitro infection model

Wednesday 15:20-16:50

III-027Laurynas Mockeliunas

Model-based assessment of early bactericidal activity of rifampicin in combination with meropenem plus amoxicillin/clavulanate among adults with rifampicin-resistant pulmonary tuberculosis

Thursday 09:50-11:20

III-032Felix Müller

Understanding variability in microdialysis measurements: introducing a combined calibration approach for piperacillin and tazobactam in LPS-induced septic piglets

Thursday 09:50-11:20

III-048Amaury O'Jeanson

Data-driven model selection for model-informed precision dosing: a case study with vancomycin

Thursday 09:50-11:20

III-049Ochuko Orherhe

Pharmacometric modelling to describe pharmacokinetics and exposure-response of ivermectin in adolescent patients infected with Trichuris trichiura

Thursday 09:50-11:20

III-072Anh Duc Pham

Population plasma and tissue pharmacokinetics of linezolid in healthy volunteers and septic patients

Thursday 09:50-11:20

III-087Quentin Renou

External evaluation of a population pharmacokinetic (POP-PK) model of Cabotegravir HIV-1-infected patients treated with long-acting Cabotegravir/Rilpivirine (LA CAB-RPV)

Thursday 09:50-11:20

III-088Juan Eduardo Resendiz Galvan

What is the effective concentration of dolutegravir? A pharmacokinetic/pharmacodynamic analysis.

Thursday 09:50-11:20

III-109Raphaël Saporta

Pharmacokinetic-pharmacodynamic modelling to characterize the time-course of meropenem effect in vivo on bacteria with high MIC

Thursday 09:50-11:20

III-111Sharon Sawe

Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy.

Thursday 09:50-11:20

III-113Carmine Schiavone

Understanding Population Heterogeneity in Vaccine-induced Immunity: A Mechanistic Model for Immune Fingerprinting

Thursday 09:50-11:20

III-114Verena Schöning

Total and unbound flucloxacillin population pharmacokinetics in patients with Staphylococcus aureus bloodstream infection

Thursday 09:50-11:20

III-116Clarisse Schumer

Building a model from comparison of SARS-CoV-2 viral dynamics model proposed since 2020: what are the main differences?

Thursday 09:50-11:20

IV-004Jérémy Seurat

Macrophage-induced reduction of bacteriophage density limits the efficacy of pulmonary phage therapy

Thursday 15:00-16:30

IV-017Britta Steffens

Pharmacometric analysis to explore moxidectin treatment with and without albendazole in Trichuris trichiura-infected adolescents

Thursday 15:00-16:30

IV-020Oleg Stepanov

Utilizing the AZD7442 Model for Accelerated New Drug Development: Pharmacokinetic Insights Across Infectious Disease Prevention and Passive Immunization

Thursday 15:00-16:30

IV-063Alberto Vegas

Modelling & simulation of biomarkers during anti-HIV monotherapy treatment

Thursday 15:00-16:30

IV-064Nieves Velez de Mendizabal

A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with chronic hepatitis D

Thursday 15:00-16:30

IV-066Bharadwaj Vemparala

Modeling the influence of antiretroviral treatment initiation time on post-treatment control of HIV infection

Thursday 15:00-16:30

IV-068Diego Vera-Yunca

Assessing clinical outcomes of nosocomial pneumonia patients with a pharmacometric multistate model

Thursday 15:00-16:30

IV-073Jannik Vollmer

Combined population PK modelling of cefepime and enmetazobactam to characterize their individual and combined PK from the phase 1 to 3 studies

Thursday 15:00-16:30

IV-075Thanakorn Vongjarudech

Evaluation of QT Prolongation During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Thursday 15:00-16:30

IV-080Shayne Watson

Population PK and PKPD modeling of TBA-7371 in Healthy Adults and Adults with tuberculosis

Thursday 15:00-16:30

IV-088Francis Williams Ojara

Population pharmacokinetic characterisation of plasma-to-breast milk transfer of lamivudine and subsequent infant exposure through breast milk

Thursday 15:00-16:30

IV-104Hinojal Zazo Gómez

Dosing evaluation of ceftazidime/avibactam in intensive care unit patients based on pharmacokinetic-pharmacodinamic (PK/PD) modelling and simulation.

Thursday 15:00-16:30